All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2020-07-08T15:22:51.000Z

The protective role of short-chain fatty acids from the development of GvHD

Jul 8, 2020
Share:

Bookmark this article

Perturbed microbiota has been associated with the establishment and progression of graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation (HSCT). Furthermore, GvHD severity has been associated with broad-spectrum antibiotic use following HSCT, and reinstatement of healthy gut microbiota is being investigated as a therapeutic approach for treating GvHD.1 These findings are undisputed, but there remain areas of uncertainty.

Short-chain fatty acids (SCFA), such as acetate, propionate, and butyrate are almost exclusively produced by the gut bacteria and have long been suspected to play a role in GvHD pathogenesis. Preclinical models have shown that butyrate supports intestinal epithelia and alters immune populations in the gastrointestinal tract. Mathilde Payen and colleagues aimed to determine whether changes in the microbiome composition with subsequent reduction of SCFAs contribute towards acute GvHD (aGvHD) onset, while a team led by Kate A. Markey focused on the potential protective role of SCFA from chronic GvHD (cGvHD) progression.1,2

The microbiome and aGvHD onset1

Study design

  • Patients with leukemia, myelodysplastic syndrome, and lymphoma receiving allogeneic HSCT (allo-HSCT) at Saint-Louis Hospital, Paris, FR, between January 21, 2013 and October 31, 2016 were considered for enrollment
  • Stool samples were taken weekly — patients who provided samples at the time of aGvHD onset (−2 /+7 days) were enrolled (n = 35)
  • A further 35 patients were selected as a non-GvHD control cohort
  • Assessment of patient microbiota was carried out using
    • next-generation sequencing (NGS) to assess fecal bacterial composition and diversity
    • real-time quantitative polymerase chain reaction (RT qPCR) to quantify microbiota composition
    • gas-liquid chromatography was used to determine the total concentrations of SCFAs: acetate, propionate, and butyrate

Results

Patient characteristics

  • Patients with aGvHD were classified by gut involvement severity:
    • Mild aGvHD (Stage 1; n = 18)
    • Severe aGvHD (Stage 2/3; n = 17)
  • Baseline patient characteristics are presented in Table 1
  • Throughout stool collection, antibiotic exposure was similar between patients with and without GvHD

Table 1. Baseline characteristics of study participants1

aGvHD, acute graft-versus-host disease; HLA, human leukocyte antigen

Patient characteristic

 

aGvHD

(n = 35)

Control

(n = 35)

Total

(N = 70)

Mean age, years (range)

49.2 (16.4–69.0)

46.7 (18.2–68.9)

47.9 (16.4–69.0)

Male gender, n

22

19

41

Transplant characteristics, %

 

Myeloablative conditioning

22.8

45.7

34.3

Total body irradiation

20.0

25.7

22.9

Steam cell source, %

Peripheral blood

77.1

74.3

75.7

Bone marrow

14.3

20.0

17.2

Cord blood

8.6

5.7

7.1

HLA match, %

Identical sibling

31.4

48.6

40.0

Matched unrelated

45.7

17.1

31.4

Mismatched unrelated

20.0

34.3

27.2

Mismatched relative

2.9

0.0

1.4

Dead at 1 year, %

45.7

25.7

35.7

aGvHD cause of death, %

68.8

0.0

44.0

 

Microbial alterations

  • When compared with patients with mild GvHD and controls, patients with severe GvHD demonstrated a significantly lower
    • bacterial count (p = 0.003)
    • microbiota α-diversity (p = 0.39)

Enteric microbiota

  • Fewer patients with severe aGvHD had bacteria of the Blautia coccoides group, an important producer of SCFA
  • Total numbers of B. coccoides (cluster XIVa) were significantly lower in patients with severe aGvHD compared with mild GvHD (p = 0.36) and the control arm (p = 0.007)

Microbiome signatures of severe aGvHD

  • A significantly reduced number of two SCFA producing families of Firmicutes, Lachnospiraceae and Ruminococcaceae, was observed in patients with severe aGvHD vs the control arm (see Table 2 for details)

Table 2. Microbiome signatures of severe aGvHD1

aGvHD, acute graft-versus-host disease; SCFA, short-chain fatty acids

*vs control patients

† Do not contribute, or contribute negatively, to SCFA production

Depleted genera

P*

SCFA production

Lachnospiraceae family

Lachnoclostridium

Blautia

Sellimonas

Anaerostipes

 

0.019

0.020

0.014

0.015

 

acetate, propionate, butyrate

acetate

acetate, butyrate

Ruminococcaceae family

Faecalibacterium UBA1819

Flavonifractor

 

0.011

0.012

 

propionate, butyrate

acetate, propionate, butyrate

Erysipelotrichaceae family

Erysipelatoclostridium

 

0.002

 

acetate

Streptococcaceae

Lactococcus

 

0.005

 

Enriched genera

 

 

Prevotella 9

0.004

Stenotrophomonas

0.009

Metabolic signatures of aGvHD

  • The total amount of the fecal SCFAs, butyrate and propionate, was significantly lower at the time of aGvHD onset and was associated with disease severity (Table 3)
  • Butyrate was significantly depleted in patients with mild aGvHD and with severe aGvHD vs control (Table 3)
  • Neither bacterial composition nor SCFA concentrations were associated with response to steroid treatment

Table 3. Metabolic signatures of aGvHD vs controls1

aGvHD, acute graft-versus-host disease; SCFAs, short-chain fatty acids

Severe aGvHD vs control

Decrease, %

P

SCFAs

80.6

0.0003

Acetate

75.8

0.002

Butyrate

94.6

0.001

Propionate

95.8

0.0009

Mild aGvHD vs control

Decrease, %

P

SCFAs

N/A

< 0.05

Butyrate

86.0

0.021

Propionate

N/A

< 0.05

Study conclusions

  • Lower bacterial biomass and species diversity was seen in severe aGvHD vs mild aGvHD and control patients
  • Depleted levels of SCFAs, specifically acetate, butyrate, and propionate, were seen in patients with severe aGvHD compared with controls
  • Reduced level of butyrate was identified as a potential marker of early aGvHD
  • Limitations of the study:
    • Low patient numbers
    • The influence of antibiotic administration on microbiota function could not be determined, as all patients received antibiotics both before and during the study follow-up

 The microbiome and cGvHD2

Study design

  • Adult patients receiving allo-HSCT at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, provided stool samples 30 days prior to, and 365 days following transplant
  • Patients who developed cGvHD with banked stool samples available (n = 54) were included in this analysis
  • A further 171 patients were selected as a control cohort
  • 16S ribosomal-RNA amplicon sequencing was performed for stool microbiome sequencing
  • Plasma samples were analyzed using a gas chromatography-quadrupole time of flight (GC-QTOF) for metabolomic analysis

Results

Patient characteristics

  • Disease characterization is presented in Table 4

Table 4. Disease characterization2

cGvHD, chronic graft-versus-host disease

*% of patients with cGvHD

Characteristic

Patients (n = 54; cGvHD, n = 45; control, n = 9)

Disease classification, %

cGvHD

-Mild*

-Moderate*

-Severe*

Late onset cGvHD

Overlap syndrome

 

42.5

53.7

16.6

14.8

14.8

42.5

Median time to cGvHD onset, days (range)

184 (55–451)

 Microbiota composition analysis

  • Similarities were observed between the cGvHD and control arms, including
    • broad spectrum antibiotic exposure
    • microbiota alpha-diversity prior to, during, and 100 days following allo-HSCT
    • rates of preceding aGvHD (peri-d100)
    • microbiota domination by Firmicutes prior to allo-HSCT
    • expansion of the Enterococcus genus in the peri-engraftment period

Peri-d100 analysis

  • Of the 225 patients enrolled in this study, 45 had samples available in the 100-day window (cGvHD, n = 9; control, n = 36)
  • An analysis of 53 peri-d100 (cGvHD, n = 10; control, n = 43) uncovered that patients who developed cGvHD demonstrated
    • significantly lower concentrations of SCFAs butyrate, propionate, and hexanoate vs controls in plasma samples
    • high abundance of the genus Akkermansia in stool samples
    • low levels of the genus Faecalibacterium, and of butyrate-producing genera, Lachnoclostridium, Clostridium, and Faecalibacterium

Study conclusions

  • Increased concentrations of the SCFAs, butyrate, and propionate, and high abundance of SCFA producing bacteria were associated with lower incidence of cGvHD

Overall conclusions

Data from these two studies suggest that depleted levels of certain microbe derived SCFAs are associated with both aGvHD establishment and cGvHD progression. These findings may help to refine novel microbiome restoration treatments, such as fecal transplantation, or SCFA supplementation to reduce the incidence of GvHD amongst patients receiving HSCT.

 

  1. Payen M, Nicolis I, Robin M, et al. Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. Blood Adv. 2020;4(9):1824-1832. DOI: 10.1182/bloodadvances.2020001531
  2. Markey KA, Schluter J, Gomes ALC, et al. Microbe-derived short chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood. 2020;136(1):130-136. DOI: 10.1182/blood.2019003369 [[references1]]

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox